Dr. Feigin is a Professor of Neurology and Molecular Medicine at the Hofstra Northwell School of Medicine. He directs the Huntington’s Disease Center at North Shore University Hospital and the Laboratory of Experimental Therapeutics for Movement Disorders at The Feinstein Institute for Medical Research of the Northwell Health System in Manhasset, NY. Dr. Feigin has been involved in Huntington’s disease (HD) clinical research for more than 20 years; he participated in the Venezuela HD project for 10 years beginning in 1993. He has been a site principal investigator on more than 30 National Institute of Health and industry sponsored clinical trials of new treatments for HD and Parkinson’s disease (PD), and he has been a principal investigator on several multicenter clinical trials for HD and PD. His independent research focuses on using state-of-the-art imaging methods to elucidate the mechanisms underlying current therapies for movement disorders. This work has led to the use of imaging as a biomarker in clinical trials of novel therapies for HD and PD. In addition, Dr. Feigin is interested in utilizing imaging as a biomarker for HD in the premanifest phase of illness. Dr. Feigin has served in many leadership roles for national and international academic consortiums studying HD including the Huntington Study Group. In addition, he remains a committed and busy clinician caring for patients and families with HD and other Movement Disorders. Karen E. Anderson, MD is Director of the Huntington Disease Care, Education and Research Center (HDCERC), a joint endeavor of Georgetown University Medical Center (GUMC) and MedStar Georgetown University Hospital.Dr. Anderson is a neuropsychiatrist with dual appointments in the departments of psychiatry and neurology; she leads a team of neurologists, psychiatrists, neuropsychologists, genetic counselors, social workers and other specialists who make up the Huntington Disease Center.Dr. Anderson's work combines her lifelong interest in behavior with an interest in understanding how disease can affect the brain and cause behavioral symptoms. In addition to seeing patients and their families, Dr. Anderson is active in research. She is currently the co-principal investigator on a clinical trial studying a medication to treat Huntington's disease, and another studying a medication for tardive dyskinesia, a neurological disorder. Dr. Anderson is also involved in research to develop treatment for the behavioral symptoms of Parkinson's disease, brain injury and Alzheimer's disease.Dr. Anderson is on the executive committee of the Huntington Study Group, a collaborative organization of physicians and healthcare providers from around the world dedicated to clinical research of Huntington's disease. She's also an affiliate member of the European Huntington's Disease Network. In 2013, the Baltimore Huntington Disease Society of America affiliate awarded her their Celebration of Hope Award for excellence in Huntington's disease clinical care.

• Section 1 Basic Science1. Genetics of Huntington disease2. Mechanisms underlying neurodegeneration in Huntington disease: Applications to novel disease-modifying therapiesSection 2 Clinical Aspects3. Epidemiology of Huntington disease4. Statistical modelling of Huntington disease onset5. The diagnosis and natural history of Huntington disease6. Preclinical cognitive and behavioral changes in Huntington disease7. Preclinical motor manifestations of Huntington disease8. The highly anxious individual presenting for Huntington disease predictive genetic testing: the psychiatrist’s role in assessment and counseling9. Reproductive options for Huntington disease families10. Genetic testing for Huntington diseaseSection 3 Treatment of Huntington Disease11. Medical treatment of behavioral manifestations of Huntington disease12. Medical management of motor manifestations of Huntington disease13. The role of rehabilitation therapy in Huntington disease14. Contemporary health care for Huntington disease15. The impact of Huntington disease on young people16. Making a measurable difference in advanced Huntington disease careSection 4 Experimental Therapeutics17. New symptomatic therapies for Huntington disease18. Motor outcome measures in Huntington disease clinical trials19. Cognitive outcome measures in Huntington disease clinical drug trialsSection 5 Biomarkers20. Structural imaging in premanifest and manifest Huntington disease21. Functional imaging in Huntington disease

Dr. Feigin is a Professor of Neurology and Molecular Medicine at the Hofstra Northwell School of Medicine. He directs the Huntington’s Disease Center at North Shore University Hospital and the Laboratory of Experimental Therapeutics for Movement Disorders at The Feinstein Institute for Medical Research of the Northwell Health System in Manhasset, NY. Dr. Feigin has been involved in Huntington’s disease (HD) clinical research for more than 20 years; he participated in the Venezuela HD project for 10 years beginning in 1993. He has been a site principal investigator on more than 30 National Institute of Health and industry sponsored clinical trials of new treatments for HD and Parkinson’s disease (PD), and he has been a principal investigator on several multicenter clinical trials for HD and PD. His independent research focuses on using state-of-the-art imaging methods to elucidate the mechanisms underlying current therapies for movement disorders. This work has led to the use of imaging as a biomarker in clinical trials of novel therapies for HD and PD. In addition, Dr. Feigin is interested in utilizing imaging as a biomarker for HD in the premanifest phase of illness. Dr. Feigin has served in many leadership roles for national and international academic consortiums studying HD including the Huntington Study Group. In addition, he remains a committed and busy clinician caring for patients and families with HD and other Movement Disorders. Karen E. Anderson, MD is Director of the Huntington Disease Care, Education and Research Center (HDCERC), a joint endeavor of Georgetown University Medical Center (GUMC) and MedStar Georgetown University Hospital.Dr. Anderson is a neuropsychiatrist with dual appointments in the departments of psychiatry and neurology; she leads a team of neurologists, psychiatrists, neuropsychologists, genetic counselors, social workers and other specialists who make up the Huntington Disease Center.Dr. Anderson's work combines her lifelong interest in behavior with an interest in understanding how disease can affect the brain and cause behavioral symptoms. In addition to seeing patients and their families, Dr. Anderson is active in research. She is currently the co-principal investigator on a clinical trial studying a medication to treat Huntington's disease, and another studying a medication for tardive dyskinesia, a neurological disorder. Dr. Anderson is also involved in research to develop treatment for the behavioral symptoms of Parkinson's disease, brain injury and Alzheimer's disease.Dr. Anderson is on the executive committee of the Huntington Study Group, a collaborative organization of physicians and healthcare providers from around the world dedicated to clinical research of Huntington's disease. She's also an affiliate member of the European Huntington's Disease Network. In 2013, the Baltimore Huntington Disease Society of America affiliate awarded her their Celebration of Hope Award for excellence in Huntington's disease clinical care.

• Section 1 Basic Science1. Genetics of Huntington disease2. Mechanisms underlying neurodegeneration in Huntington disease: Applications to novel disease-modifying therapiesSection 2 Clinical Aspects3. Epidemiology of Huntington disease4. Statistical modelling of Huntington disease onset5. The diagnosis and natural history of Huntington disease6. Preclinical cognitive and behavioral changes in Huntington disease7. Preclinical motor manifestations of Huntington disease8. The highly anxious individual presenting for Huntington disease predictive genetic testing: the psychiatrist’s role in assessment and counseling9. Reproductive options for Huntington disease families10. Genetic testing for Huntington diseaseSection 3 Treatment of Huntington Disease11. Medical treatment of behavioral manifestations of Huntington disease12. Medical management of motor manifestations of Huntington disease13. The role of rehabilitation therapy in Huntington disease14. Contemporary health care for Huntington disease15. The impact of Huntington disease on young people16. Making a measurable difference in advanced Huntington disease careSection 4 Experimental Therapeutics17. New symptomatic therapies for Huntington disease18. Motor outcome measures in Huntington disease clinical trials19. Cognitive outcome measures in Huntington disease clinical drug trialsSection 5 Biomarkers20. Structural imaging in premanifest and manifest Huntington disease21. Functional imaging in Huntington disease

Dr. Feigin is a Professor of Neurology and Molecular Medicine at the Hofstra Northwell School of Medicine. He directs the Huntington’s Disease Center at North Shore University Hospital and the Laboratory of Experimental Therapeutics for Movement Disorders at The Feinstein Institute for Medical Research of the Northwell Health System in Manhasset, NY. Dr. Feigin has been involved in Huntington’s disease (HD) clinical research for more than 20 years; he participated in the Venezuela HD project for 10 years beginning in 1993. He has been a site principal investigator on more than 30 National Institute of Health and industry sponsored clinical trials of new treatments for HD and Parkinson’s disease (PD), and he has been a principal investigator on several multicenter clinical trials for HD and PD. His independent research focuses on using state-of-the-art imaging methods to elucidate the mechanisms underlying current therapies for movement disorders. This work has led to the use of imaging as a biomarker in clinical trials of novel therapies for HD and PD. In addition, Dr. Feigin is interested in utilizing imaging as a biomarker for HD in the premanifest phase of illness. Dr. Feigin has served in many leadership roles for national and international academic consortiums studying HD including the Huntington Study Group. In addition, he remains a committed and busy clinician caring for patients and families with HD and other Movement Disorders. Karen E. Anderson, MD is Director of the Huntington Disease Care, Education and Research Center (HDCERC), a joint endeavor of Georgetown University Medical Center (GUMC) and MedStar Georgetown University Hospital.Dr. Anderson is a neuropsychiatrist with dual appointments in the departments of psychiatry and neurology; she leads a team of neurologists, psychiatrists, neuropsychologists, genetic counselors, social workers and other specialists who make up the Huntington Disease Center.Dr. Anderson's work combines her lifelong interest in behavior with an interest in understanding how disease can affect the brain and cause behavioral symptoms. In addition to seeing patients and their families, Dr. Anderson is active in research. She is currently the co-principal investigator on a clinical trial studying a medication to treat Huntington's disease, and another studying a medication for tardive dyskinesia, a neurological disorder. Dr. Anderson is also involved in research to develop treatment for the behavioral symptoms of Parkinson's disease, brain injury and Alzheimer's disease.Dr. Anderson is on the executive committee of the Huntington Study Group, a collaborative organization of physicians and healthcare providers from around the world dedicated to clinical research of Huntington's disease. She's also an affiliate member of the European Huntington's Disease Network. In 2013, the Baltimore Huntington Disease Society of America affiliate awarded her their Celebration of Hope Award for excellence in Huntington's disease clinical care.

• Section 1 Basic Science1. Genetics of Huntington disease2. Mechanisms underlying neurodegeneration in Huntington disease: Applications to novel disease-modifying therapiesSection 2 Clinical Aspects3. Epidemiology of Huntington disease4. Statistical modelling of Huntington disease onset5. The diagnosis and natural history of Huntington disease6. Preclinical cognitive and behavioral changes in Huntington disease7. Preclinical motor manifestations of Huntington disease8. The highly anxious individual presenting for Huntington disease predictive genetic testing: the psychiatrist’s role in assessment and counseling9. Reproductive options for Huntington disease families10. Genetic testing for Huntington diseaseSection 3 Treatment of Huntington Disease11. Medical treatment of behavioral manifestations of Huntington disease12. Medical management of motor manifestations of Huntington disease13. The role of rehabilitation therapy in Huntington disease14. Contemporary health care for Huntington disease15. The impact of Huntington disease on young people16. Making a measurable difference in advanced Huntington disease careSection 4 Experimental Therapeutics17. New symptomatic therapies for Huntington disease18. Motor outcome measures in Huntington disease clinical trials19. Cognitive outcome measures in Huntington disease clinical drug trialsSection 5 Biomarkers20. Structural imaging in premanifest and manifest Huntington disease21. Functional imaging in Huntington disease